Apyx Medical Corp

Apyx Medical Corp. operates as an energy-based medical technology company. The firm engages in developing, manufacturing, and marketing a range of electrosurgical products and technologies, as well as related medical products used the offices of doctors, surgery centers, and hospitals worldwide. It operates through the following segments: Advanced Energy and Original Equipment Manufacture (OME). The company was founded by Andrew Makrides in 1978 and is headquartered in Clearwater, FL.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Apyx Medical Corp reports Q4 revenue decline, eyes 2023 growth

Apyx Medical Corp faced revenue challenges in Q4 2022, but secured new clearances and credit facilities.
The company anticipates improved revenue and profitability in 2023 with strategic initiatives.
Despite losses and reduced cash reserves, Apyx aims to enhance product offerings and financial stability.
Management's actions aim to address concerns and position the company for growth in 2023.

Apyx Medical Corp reports Q1 revenue beat but faces cost challenges

Apyx Medical Corp faced mixed results in Q1 2023 with revenue exceeding expectations but a decline in gross profit and net loss.
The company showcased strengths in OEM sales, product launches, and property transactions, while grappling with challenges in certain sales segments.
With revised revenue guidance, margin expectations, and growth opportunities, Apyx has a strategic roadmap for future performance improvements.

Apyx Medical Corp reports strong Q2 growth and reaffirms 2023 guidance

Apyx Medical Corp demonstrated robust growth in Q2 2023, driven by Advanced Energy product sales and operational efficiency improvements.
While facing challenges in certain regions and managing operating expenses, the company's strategic initiatives and revenue diversification are key strengths.
With reaffirmed financial guidance and opportunities for market expansion, Apyx is poised for continued growth and innovation in the medical device industry.

Apyx Medical Corp reports robust Q3 performance and strategic initiatives

Apyx Medical Corp's Q3 2023 earnings call showcased strong revenue growth, improved gross profit margins, and strategic initiatives to address challenges. With a focus on operational efficiency and new product introductions, the company aims to drive future growth and profitability.

Apyx Medical Corp reports strong Q4 revenue growth and eyes market expansion

Apyx Medical Corp delivered strong revenue growth in Q4 2023 driven by Advanced Energy products and international sales performance.
While facing challenges in net loss and operating expenses, the company's technology and clinical support remain key strengths.
Opportunities lie in financial growth targets, market recognition, and leveraging positive feedback to drive future success.
Overall, Apyx Medical Corp's performance reflects resilience and potential for growth in the medical technology sector.

Apyx Medical Corp reports Q1 revenue decline, focuses on cost control

Apyx Medical Corp faced revenue decline in Q1 2024, driven by lower Advanced Energy sales.
The company showcased strengths in cost control, operational achievements, and revenue diversification.
Challenges include declining Advanced Energy sales and a projected net loss for 2024.
Opportunities lie in driving Renuvion technology adoption and addressing segment sales challenges.

Apyx Medical Corp reports Q3 revenue decline, bets on Ayon

Apyx Medical Corp's Q3 2024 performance reflects a mixed financial picture with revenue decline but promising growth in key segments like disposable handpieces.
Management's strategic initiatives, including the Ayon system launch and cost-saving measures, aim to drive future growth and achieve cash flow breakeven by 2027.
While facing revenue challenges and financial losses, the company's focus on operational efficiency and product innovation presents opportunities for long-term success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

CLEARWATER, Fla.--(BUSINESS WIRE)--Apyx Medical Corporation (NASDAQ:APYX) (the “Company”), the manufacturer of a proprietary helium plasma and radiofrequency technology marketed and sold as Renuvion®, today announced that financial results for the fourth quarter and fiscal year 2022 will be released before the market opens on Thursday, March 16th. Management will host a conference call at 8:00 a.m.

Apyx Medical Corporation to Release Fourth Quarter and Fiscal Year 2022 Financial Results on March 16, 2023

Episode to Feature Beverly Hills Plastic Surgeon Dr. Charles J. Galanis  Performing Renuvion's Minimally Invasive Neck Procedure  on Patient CLEARWATER, Fla.

RENUVION® COSMETIC NECK LAXITY PROCEDURE TO BE FEATURED ON 'THE BALANCING ACT' TALK SHOW ON LIFETIME® FEBRUARY 13

CLEARWATER, Fla.--( BUSINESS WIRE )--Apyx Medical Corporation (NASDAQ:APYX) (the “Company”), the manufacturer of a proprietary helium plasma and radiofrequency technology marketed and sold as Renuvion®, today announced it has submitted a 510(k) premarket notification (“510(k) submission”) for the Renuvion APR Handpiece to the U.S. Food and Drug Administration (“FDA”), supported by a clinical study and real-world evidence. The 510(k) submission is intended to expand Renuvion's indications for use to include a specific indication for the use of the Renuvion APR Handpiece for the coagulation of subcutaneous soft tissues where needed, following liposuction.

Apyx Medical Corporation Announces FDA 510(k) Submission for the Use of the Renuvion® APR Handpiece for the Coagulation of Subcutaneous Soft Tissues Where Needed, Following Liposuction

FDA-Cleared, All-in-One Advanced Energy System Now Available for Medical Professionals CLEARWATER, Fla. , Jan. 25, 2023 /PRNewswire/ -- Apyx Medical Corporation (NASDAQ: APYX) (the "Company"), the manufacturer of a proprietary helium plasma and radiofrequency technology marketed and sold as Renuvion®, today announced the launch of its latest-generation Renuvion generator, the Apyx One Console, in the United States.

APYX MEDICAL CORPORATION LAUNCHES NEW 'APYX ONE CONSOLE' FOR COSMETIC SURGICAL PROCEDURES IN THE UNITED STATES

CLEARWATER, Fla.--( BUSINESS WIRE )--Apyx Medical Corporation (NASDAQ:APYX) (the “Company”), the manufacturer of a proprietary helium plasma and radiofrequency technology marketed and sold as Renuvion®, today reported preliminary revenue results for the fourth quarter and full year ended December 31, 2022.

Apyx Medical Corporation Reports Preliminary Fourth Quarter and Full Year 2022 Revenue Results

Direct-to-Consumer Marketing Shows How Results Can Be Achieved Using Minimally Invasive Technology CLEARWATER, Fla. , Jan. 3, 2023 /PRNewswire/ -- Apyx® Medical Corporation (NASDAQ: APYX), the manufacturer of Renuvion®, a proprietary helium plasma and radiofrequency technology, today announces the launch of its first-ever direct-to-consumer brand campaign.

APYX® MEDICAL CORPORATION EMBARKS ON INAUGURAL BRAND CAMPAIGN FOR RENUVION®

Fintel reports that Archon Capital Management LLC has filed a 13G/A form with the SEC disclosing ownership of 3,452,030 shares of Apyx Medical Corp (APYX).

Archon Capital Ups Stake in Apyx Medical (APYX) After Q3 Results

CLEARWATER, Fla.--( BUSINESS WIRE )--Apyx Medical Corporation (NASDAQ:APYX) (the “Company”), the manufacturer of a proprietary helium plasma and radiofrequency technology marketed and sold as Renuvion®, announced today that management will participate in the Piper Sandler 34th Annual Healthcare Conference, which is being held at the Lotte New York Palace in New York, NY. Management will participate in fireside chat on Wednesday, November 30 at 11:00 a.m. ET.

Apyx Medical Corporation to Participate in the Piper Sandler 34th Annual Healthcare Conference

Apyx Medical Corporation (NASDAQ:APYX ) Q3 2022 Earnings Conference Call November 10, 2022 8:00 AM ET Company Participants Charles Goodwin - President and Chief Executive Officer Tara Semb - Chief Financial Officer Conference Call Participants Matt Hewitt - Craig-Hallum Capital Group Matthew O'Brien - Piper Sandler Kyle Bauser - Lake Street Capital Markets Dave Turkaly - JMP Securities Russell Cleveland - RENN Capital Operator Hello and welcome, ladies and gentlemen to Third Quarter of 2022 Earnings Conference Call for Apyx Medical Corporation. At this time, all participants have been placed in listen-only mode.

Apyx Medical Corporation (APYX) Q3 2022 Earnings Call Transcript

Apyx (APYX) delivered earnings and revenue surprises of -41.67% and 24.05%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Apyx Medical (APYX) Reports Q3 Loss, Misses Revenue Estimates

Apyx Medical Corporation Reports Third Quarter 2022 Financial Results and Updates Full Year 2022 Financial Outlook

CLEARWATER, Fla.--(BUSINESS WIRE)--Apyx Medical Corporation (NASDAQ:APYX) (the “Company”), the manufacturer of a proprietary helium plasma and radiofrequency technology marketed and sold as Renuvion®, today announced that financial results for the third quarter of fiscal year 2022 will be released before the market opens on Thursday, November 10th. Management will host a conference call at 8:00 a.m. Eastern Time on November 10th to discuss the results of the quarter and host a question and answ

Apyx Medical Corporation to Release Third Quarter of Fiscal Year 2022 Financial Results on November 10, 2022

Doctors Attest to Advanced Energy Technology Device's Transformative Solutions to Achieve Desired Results in Patients CLEARWATER, Fla. , Sept. 13, 2022 /PRNewswire/ -- Apyx Medical Corporation (NASDAQ: APYX) (the "Company"), the manufacturer of a proprietary helium plasma and radiofrequency technology marketed and sold as Renuvion®, today announced the release of a new surgeon testimonial video featuring its Renuvion Helium Plasma Technology.

'BOTCHED' TV STAR DR. PAUL NASSIF AMONG TOP U.S. PLASTIC SURGEONS USING RENUVION® HELIUM PLASMA TECHNOLOGY IN COSMETIC PROCEDURES

CLEARWATER, Fla.--(BUSINESS WIRE)--Apyx Medical Corporation (NASDAQ:APYX) (the “Company”), the manufacturer of a proprietary helium plasma and radiofrequency technology marketed and sold as Renuvion®, announced today that management will participate in the Lake Street Best Ideas Growth Conference, which is being held at The Yale Club in New York, NY on Wednesday, September 14th. Management will participate in 1x1 meetings. There will be no formal presentation. About Apyx Medical Corporation: Ap

Apyx Medical Corporation to Participate in the Lake Street Best Ideas Growth Conference

Apyx Medical Corporation (NASDAQ:APYX ) Q2 2022 Earnings Conference Call August 11, 2022 5:00 PM ET Company Participants Charles Goodwin – President and Chief Executive Officer Tara Semb – Chief Financial Officer Conference Call Participants Dave Turkaly – JMP Securities Matt Hewitt – Craig-Hallum Capital Group Kyle Bauser – Lake Street Capital Operator Hello, and welcome, ladies and gentlemen, to the Second Quarter of 2022 Earnings Conference Call for Apyx Medical Corporation. At this time, all participants have been placed in a listen-only mode.

Apyx Medical Corporation (APYX) CEO Charles Goodwin on Q2 2022 Results - Earnings Call Transcript

CLEARWATER, Fla.--(BUSINESS WIRE)--Apyx Medical Corporation (NASDAQ:APYX) (the “Company”), the manufacturer of a proprietary helium plasma and radiofrequency technology marketed and sold as Renuvion®, today reported financial results for its second quarter ended June 30, 2022, and updated financial expectations for the full year ending December 31, 2022. Second Quarter 2022 Financial Summary: Total revenue of $10.3 million, down 8% year-over-year. Advanced Energy revenue of $8.4 million, down 1

Apyx Medical Corporation Reports Second Quarter 2022 Financial Results and Updates Full Year 2022 Financial Outlook

NEW YORK , Aug. 5, 2022 /PRNewswire/ -- Jakubowitz Law announces that a securities fraud class action lawsuit has commenced on behalf of shareholders of Apyx Medical Corporation (NASDAQ: APYX). To receive updates on the lawsuit, fill out the form: https://claimyourloss.com/securities/apyx-medical-corporation-loss-submission-form/?id=30555&from=4 The lawsuit seeks to recover losses for shareholders who purchased Apyx between May 12, 2021 and March 11, 2022.

APYX SHAREHOLDER ALERT: Jakubowitz Law Reminds Apyx Shareholders of a Lead Plaintiff Deadline of August 5, 2022

Los Angeles, California--(Newsfile Corp. - August 5, 2022) - The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Apyx Medical Corporation ("Apyx" or "the Company") (NASDAQ: APYX) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.

DEADLINE TODAY: The Schall Law Firm Encourages Investors in Apyx Medical Corporation with Losses of $100,000 to Contact the Firm

New York, New York--(Newsfile Corp. - August 4, 2022) - Levi & Korsinsky, LLP notifies investors in Apyx Medical Corporation (NASDAQ: APYX) ("Apyx" or the "Company") of a class action securities lawsuit.The lawsuit on behalf of Apyx investors has been commenced in the the United States District Court for the Middle District of Florida. Affected investors purchased or otherwise acquired certain Apyx Medical Corporation securities between May 12, 2021 and March 11, 2022.

Apyx Class Action: Levi & Korsinsky Reminds Apyx Medical Corporation Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of August 5, 2022 - APYX

New York, New York--(Newsfile Corp. - August 4, 2022) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Apyx Medical Corporation (NASDAQ: APYX) between May 12, 2021 and March 11, 2022, both dates inclusive (the "Class Period"), of the important August 5, 2022 lead plaintiff deadline.

APYX DEADLINE TOMORROW: ROSEN, A TOP RANKED FIRM, Encourages Apyx Medical Corporation Investors With Losses to Secure Counsel Before Important August 5 Deadline in Securities Class Action - APYX

LOS ANGELES--(BUSINESS WIRE)--The Law Offices of Frank R. Cruz reminds investors of the upcoming August 5, 2022 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who acquired Apyx Medical Corporation (“Apyx” or the “Company”) (NASDAQ: APYX) securities between May 12, 2021 and March 11, 2022, inclusive (the “Class Period”). If you are a shareholder who suffered a loss, click here to participate. On March 14, 2022, Apyx disclosed that the U.S. Food and Drug

The Law Offices of Frank R. Cruz Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Apyx Medical Corporation (APYX)

LOS ANGELES--(BUSINESS WIRE)---- $APYX #APYX--The Schall Law Firm Encourages Investors in Apyx Medical Corporation with Losses of $100,000 to Contact the Firm

INVESTIGATION REMINDER: The Schall Law Firm Encourages Investors in Apyx Medical Corporation with Losses of $100,000 to Contact the Firm

Los Angeles, California--(Newsfile Corp. - August 4, 2022) - The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Apyx Medical Corporation ("Apyx" or "the Company") (NASDAQ: APYX) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.

DEADLINE TOMORROW: The Schall Law Firm Encourages Investors in Apyx Medical Corporation with Losses of $100,000 to Contact the Firm

NEW YORK , Aug. 4, 2022 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Apyx Medical Corporation ("Apyx" or the "Company") (NASDAQ: APYX) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Apyx investors who were adversely affected by alleged securities fraud between May 12, 2021 and March 11, 2022.

APYX LAWSUIT ALERT: Levi & Korsinsky Notifies Apyx Medical Corporation Investors of a Class Action Lawsuit and Upcoming Deadline

Los Angeles, California--(Newsfile Corp. - August 3, 2022) - The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Apyx Medical Corporation ("Apyx" or "the Company") (NASDAQ: APYX) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.

News for Apyx Medical Corp Stock (APYX)